[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cedars-Sinai Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,88,0,25,[9,50,79,109,135,157,182,210,232,256,280,302,325,356,379,399,429,451,475,497,521,543,565,588,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100644840","phase-2-ongoing-lung-decline-with-age-intensified-response-100644840",false,"NCT07676435","Ongoing Lung Decline With Age Intensified Response","A PHASE II, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE ONGOING LUNG DECLINE WITH AGE INTENSIFIED RESPONSE (OLD AIR)","OLD AIR","Inclusion Criteria:\n\n* Adults aged 60 years and older who are physically capable of participating in study procedures;\n* Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\\\u003C5-pound change);\n* No blood donation within 2 months before screening; absence of unstable chronic disease;\n* Willing to maintain baseline activity level throughout the study;\n* Body mass index \\\u003C30 kg\u002Fm²;\n* Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.\n\nExclusion Criteria:\n\n* Electrocardiogram (ECG) abnormalities, including prolonged QTc.\n* Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.\n* Resting systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>110 mmHg.\n* Known allergy or hypersensitivity to fisetin or any component of the study product.\n* Active malignancy, except non-melanoma skin cancer.\n* Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.\n* Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.\n* Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.\n* History of diverticulitis or diverticulosis with gastrointestinal bleeding.\n* Current use of systemic corticosteroids.\n* Current use of warfarin.\n* Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.\n* Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.\n* Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.\n* Unwillingness or inability to provide informed consent.\n* Pregnancy or breastfeeding.\n* Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.",true,"ALL","60 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course \"hit-and-run\" dosing strategy (approximately 20 mg\u002Fkg\u002Fday orally for 2 consecutive days on Days 1-2 and Days 8-9).",[29],"Age-Related Lung Function Decline",[31,32,33,34,35,36],"Aging","Cellular Senescence","Healthy Aging","Smoking-Related Lung Function Decline","Pulmonary Function","Smoking","RECRUITING","2026-06-30",{"date":40,"type":41},"2026-07-01","ACTUAL",{"date":43,"type":41},"2026-06-17",{"date":45,"type":23},"2027-07-15",{"name":47,"class":48},"Cedars-Sinai Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100610115","phase-2-high-cardiovascular-risk-intervention-with-cardio-oncology-consultation-for-prostate-cancer-following-androgen-receptor-pathway-inhibitor-arpi-therapy-heart-safe-100610115","NCT07223385","High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)","Inclusion Criteria:\n\n* Prostate cancer with localized, very-high risk, lymph-node positive, and\u002For metastatic (Stage IV) disease.\n* Being treated with ARPI therapy with intended duration ≥ 18 months.\n* Age \\> 65 years old and at least one CV risk factor, or age 45-65 years with at least two CV risk factors:\n\n  * Hypertension\n  * Hyperlipidemia\n  * Diabetes mellitus\n  * Family history of early CAD (male first-degree relative (father or brother) with CAD before age 55; female first-degree relative (mother or sister) with CAD before age 65)\n  * Presence of coronary artery calcium (CAC) on chest CT imaging\n* ECOG 0-2\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Prior ARPI therapy exposure \\> 6 months duration.\n* Established care with cardio-oncologist (cardiologist with expertise in CV risks of cancer and cardiotoxic cancer therapies).","MALE","45 Years",{"count":59,"type":23},80,[26],"In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death. Both pre-existing CVD and the use of androgen deprivation therapy (ADT)-a key cornerstone of treatment for men with locally advanced or metastatic PC1,2 contribute to increased CV risk. ADT has been associated with adverse metabolic effects, including increased central adiposity, elevated low-density lipoprotein (LDL) levels, impaired glycemic control, and arterial wall remodeling and endothelial dysfunction\n\nThe data demonstrates that for most patients, the status quo is insufficient6 and there remains a critical gap in the early identification of high CV-risk PC patients who may benefit most from aggressive risk mitigation strategies. Mitigation strategies, like the addition of statins as primary prevention, have shown decrease in MI\u002FCHD death across thousands of patients. Age-related expansion of hematopoietic clones carrying recurrent somatic mutations, termed clonal hematopoiesis of indeterminate potential (CHIP) has recently been identified as a significant driver of atherosclerosis, doubling the risk of coronary heart disease. Notably, while CHIP is detectable in \\~10% of persons over 70 years old, it is enriched in patients with solid malignancies, and radiotherapy exposure is among the most decisive risk factors for developing CHIP12-15. The inflammation-related metabolic signals are activated androgen signaling and exacerbated in patients with CHIP. However, the mechanistic link and clinical consequence are less understood. Therefore, it is critical to study the CV impact of CHIP and metabolic perturbations in patients with PC treated with ARSI therapy.\n\nWe plan to address these critical gaps by testing our innovative hypothesis that early cardio-oncology intervention with aggressive guidelines-based CV optimization during ARPI therapy will reduce CV risk and that CHIP and metabolomics will help identify adverse metabolic remodeling to improve CV risk prediction.\n\nRobust epidemiological and clinical trial data consistently demonstrate that patients with PC are poorly optimized from a CV risk modification perspective, and existing CV risk models do not perform well in patients with cancer. The data demonstrates that for most patients, the status quo is insufficient and there remains a critical gap in the early identification of high CV-risk PC patients who may benefit most from aggressive risk mitigation strategies.",[63,64,65],"Prostate Cancer (Diagnosis)","Prostate Cancer Stage IV","CV Risk",[67,68,69,70],"High-Risk","Lymph-node positive","ARPI Therapy","CV Risk Factors","2026-06-24",{"date":73,"type":41},"2026-06-29",{"date":75,"type":23},"2026-08-01",{"date":77,"type":23},"2030-08",{"name":47,"class":48},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":24,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":49},"100644584","online-pain-education-for-crohns-disease-and-ulcerative-colitis-100644584","NCT07671313","Online Pain Education for Crohn's Disease and Ulcerative Colitis","Randomized Controlled Trial of Online Pain Education Programs for Inflammatory Bowel Disease","Inclusion Criteria:\n\n* Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis\n* Chronic pain (visceral and\u002For somatic) related to IBD for at least 3 months\n* NIH PROMIS Pain Interference scale T-score ≥60\n* Medically stable, defined as:\n\n  1. No acute IBD-related hospitalization within the past 3 months; AND\n  2. No planned IBD surgery or planned therapeutic escalation within the next 2 months, including initiation of a new advanced therapy, dose escalation or switch of advanced therapy, or corticosteroid taper\n* Able to understand and complete questionnaires independently in English\n* Access to an internet-enabled device for online surveys and intervention access.\n\nExclusion Criteria:\n\n* Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation\n* Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia\n* Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain","18 Years",{"count":88,"type":23},60,[90],"NA","Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take about 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.",[93,94,95],"Crohn's Disease","Ulcerative Colitis (UC)","Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)",[97,98,99],"Pain Education","Remote Monitoring","Chronic pain","NOT_YET_RECRUITING","2026-06-22",{"date":103,"type":41},"2026-06-26",{"date":105,"type":23},"2026-08",{"date":107,"type":23},"2027-09",{"name":47,"class":48},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":19,"minAge":57,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":49},"100510698","impact-of-protect-your-colon-on-crc-screening-100510698","NCT05929820","Impact of Protect Your Colon™ on CRC Screening","Pilot Randomized Controlled Trial Assessing the Impact of Protect Your Colon™ on Colorectal Cancer Screening Behaviors","Inclusion Criteria:\n\n* Individuals 45 to 75 years old\n* No prior CRC screening or not up-to-date with CRC screening\n* Not at high risk for CRC (e.g., inflammatory bowel disease, colon polyposis syndromes, family history of CRC)\n* No prior colon polyps\n* Additional inclusion criteria for participants recruited through Cint online survey panels: (i) appointment with a primary care provider up to 6 weeks from time of screening, and (ii) have Preferred Provider Organization (PPO) insurance.\n\nExclusion Criteria:\n\n* Does not speak English\n* Does not have internet access\n* Any records flagged \"break the glass\" or \"research opt out.\"","75 Years",{"count":118,"type":23},184,[90],"The purpose of the research is to assess the impact of Protect Your Colon™, a colorectal cancer (CRC) screening decision aid, on patients' CRC screening behaviors. The Investigators hypothesize that Protect Your Colon™, through optimizing shared decision making, will lead to selection of a test that accurately matches patients' values and increase CRC screening uptake. To test this hypothesis, the investigators will conduct a pilot randomized controlled trial (RCT) to assess if provision of Protect Your Colon™ improves communication on CRC screening, intent to complete screening, and ultimately uptake of screening vs. usual care.",[122],"Colorectal Cancer Screening",[124,125,126,127],"Decision aid","Stool test","Colonoscopy","CT scan",{"date":129,"type":41},"2026-06-25",{"date":131,"type":41},"2023-09-28",{"date":133,"type":23},"2026-09-22",{"name":47,"class":48},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":24,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":49},"100233562","assessment-of-transcatheter-and-surgical-aortic-bioprosthetic-valve-thrombosis-and-its-treatment-with-anticoagulation-100233562","NCT02318342","Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation","Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Dysfunction With Multimodality Imaging and Its TrEatment With Anticoagulation","RESOLVE","Inclusion Criteria:\n\n* Presence of transcatheter or surgical bioprosthetic aortic valve implanted at least 48 hours prior to enrollment\n* Age 18 years or older\n* Ability to provide informed consent and follow-up with protocol procedures.\n\nExclusion Criteria:\n\n* Renal insufficiency (creatinine \\> 1.5 mg\u002FdL)\n* Known allergy to iodinated contrast agents",{"count":144,"type":23},3000,[90],"This is a prospective study designed to evaluate the structural and functional integrity of transcatheter or surgical bioprosthetic valves with multimodality imaging. The study further aims to confirm resolution of the early bioprosthetic valve thrombotic changes with anticoagulation.",[148],"Prosthetic Valve Thrombosis","2026-06-15",{"date":151,"type":41},"2026-06-16",{"date":153,"type":4},"2014-12",{"date":155,"type":23},"2028-12",{"name":47,"class":48},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":49},"100637625","transcatheter-vs-surgical-treatment-of-degenerative-mitral-regurgitation-100637625","NCT07605715","Transcatheter vs. Surgical Treatment of Degenerative Mitral Regurgitation","Transcatheter vs. Surgical Treatment of Degenerative Mitral Regurgitation: A Comparative Study of Clinical Outcomes, Patient Experiences, and Mechanistic Insights With Multimodality Imaging","DMR","Inclusion Criteria:\n\n* Patients older than 60 years who have DMR will be included in the study\n\nExclusion Criteria:\n\n* Patients with prior history of mitral intervention or surgery will be excluded.\n* Patient records flagged \"break the glass\" or \"research opt out\" will be excluded.\n* Persons with allergy to animal dander or animal-instigated asthma will be excluded.",{"count":88,"type":23},"OBSERVATIONAL","The goal of this observational study is to compare the outcomes of transcatheter edge-to-edge repair (TEER) versus surgical mitral valve repair for degenerative mitral regurgitation (DMR) over the long term. The study aims to:\n\n1. Evaluate the effectiveness and safety of TEER versus surgery in patients with DMR over long term.\n2. Investigate the predictors of left ventricular dysfunction and clinical outcomes using advanced imaging techniques, such as cardiac MRI\n3. Assess patient-reported recovery and quality of life outcomes using validated tools.\n\nThe study focuses on improving care strategies for patients with DMR, particularly those at higher surgical risk, by identifying optimal treatment approaches and predictors of recovery.",[169],"Degenerative Mitral Valve Disease",[171,172,173],"TEER","Transcatheter mitral repair","Surgical mitral repair","2026-05-18",{"date":176,"type":41},"2026-05-26",{"date":178,"type":41},"2025-02-19",{"date":180,"type":23},"2027-08",{"name":47,"class":48},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":49},"100638123","active-vs-passive-vr-during-office-based-ent-procedures-100638123","NCT07599826","Active vs. Passive VR During Office-based ENT Procedures","Active vs. Passive Virtual Reality for Reducing Pain and Anxiety During Office-based ENT Procedures","Inclusion Criteria Active and Passive VR:\n\n* Individuals 18 years old and older are included\n* Individuals undergoing the following common office-based ENT procedures: turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation (Rhineaer\u002FVivaer), nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection\n* Able to consent\n* English speaking\n\nExclusion Criteria Active VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, vertigo, or inability to use a handheld controller\n* Any records flagged \"break the glass\" or \"research opt out.\"\n\nExclusion Criteria Passive VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, or vertigo\n* Any records flagged \"break the glass\" or \"research opt out.\"",{"count":190,"type":23},132,[90],"The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.",[194,195,196,197,198,199,200,201],"Pain","Anxiety","Chronic Rhinosinusitis (CRS)","Nasal Obstruction","Nasal Polyp","Eustachian Tube Dysfunction","Dysphonia","Subglottic Stenosis (SGS)","2026-05-14",{"date":204,"type":41},"2026-05-20",{"date":206,"type":23},"2026-06",{"date":208,"type":23},"2027-12",{"name":47,"class":48},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":24,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100637535","phase-2-beta-3-enhanced-autonomic-therapy-for-pots-100637535","NCT07585513","Beta-3 Enhanced Autonomic Therapy for POTS","A Randomized Placebo-Controlled Clinical Trial Evaluating Mirabegron's Effectiveness in Alleviating POTS Symptoms","BEAT-POTS","Inclusion Criteria:\n\n1. Provision of a signed and dated informed consent form.\n2. Male or female, age ≥ 18 years old.\n3. Confirmed POTS diagnosis, which includes chronic (\\>3 months) orthostatic intolerance, an increase in heart rate (HR) of ≥30 beats per minute (bpm) without orthostatic hypotension (\\>20 mmHg drop of systolic BP) during orthostatic tests.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.\n2. Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illnesses requiring hospitalization)\n3. Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)18\n4. Active thyrotoxicosis\n5. Any experimental medication concomitantly or within 4 weeks of participation in the study\n6. Currently participating in a different clinical trial\n7. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n8. Hepatic disease (Child-Pugh Class C)\n9. Prisoners\n10. Pregnant\n11. Breastfeeding\n12. Cannot speak, write, or answer questions in English (Validated symptom questionnaires used in this study are available only in English.)\n13. Does not have the capacity to consent\n14. Patients who are known to be allergic to mirabegron or skin patch electrodes\n15. Patients taking codeine, oxycodone, thioridazine, flecainide, propafenone, and digoxin. (see explanation below)",{"count":219,"type":23},36,[26],"The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.",[223],"Postural Orthostatic Tachycardia Syndrome (POTS)","2026-05-09",{"date":226,"type":41},"2026-05-13",{"date":228,"type":23},"2026-05",{"date":230,"type":23},"2028-05",{"name":47,"class":48},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":19,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":24,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":253,"leadSponsor":255,"locationsCount":49},"100624771","tavr-vs-savr-in-severe-bicuspid-aortic-stenosis-100624771","NCT07413965","TAVR vs SAVR in Severe Bicuspid Aortic Stenosis","Bicuspid Aortic Valve Replacement: EvaLuatIon of transcathetEr VERsus Surgery (BELIEVERS) Trial","BELIEVERS","Inclusion Criteria:\n\n1. 50 years of age or older at time of consent\n2. Severe AS deemed suitable for a bioprosthesis by a local heart team (unsuitable or patient declined a mechanical valve or Ross procedure, following demonstration of evidence-based shared decision making with a validated decision-aid(1)\n3. Gated contrast CT available and suitable for core laboratory analysis;\n4. BAV anatomy confirmed by CT core laboratory analysis\n\nExclusion Criteria:\n\n1. Recent cardiovascular intervention within 30 days prior to randomization.\n2. Presence of an existing TAVR or SAVR device\n3. Pregnancy or lactation\n4. Extreme or prohibitive TAVR or SAVR risk, adjudicated by Patient Selection Committee (PSC) Review\n5. Active enrollment in another investigational study\n6. Disproportionate TAVR vs SAVR risk, as adjudicated by the patient selection committee\n7. Associated aortopathy (AA≥45mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA\\\u003C45mm but site plan for surgery of the aorta in the event of randomization to surgery\n8. Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair)\n9. In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG)\n10. Plan to use any device other than commercially approved Edwards balloon expandable or Medtronic self-expanding TAVR\n11. Leukopenia (WBC \\\u003C 3000 cells\u002FµL), anemia (Hgb \\\u003C 8 g\u002FdL), Thrombocytopenia (Plt \\\u003C 50,000 cells\u002FµL) on latest available labs within 30 days prior to randomization\n12. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days prior to randomization\n13. LVEF \\\u003C 25% within 90 days prior to randomization\n14. Stroke or transient ischemic attack (TIA) within 90 days prior to randomization\n15. Renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin per the Cockcroft-Gault formula)\n16. Severe lung disease (FEV1 \\\u003C 50% predicted), unresolved prior to randomization\n17. History of liver disease defined as MELD Score ≥ 10 or Child-Pugh Class B or C\n18. Unable to complete the KCCQ due cognitive impairment or other medical condition","50 Years",{"count":242,"type":23},1200,[90],"The study is a multicenter, randomized superiority trial of standard of care therapies for severe aortic stenosis (AS) in patients with a bicuspid aortic valve (BAV).\n\nThe two primary comparators in this study are: Transcatheter Aortic Valve Replacement (TAVR), and Surgical Aortic Valve Replacement (SAVR).\n\nTAVR is a minimally invasive transcatheter procedure to treat aortic valve disease..\n\nSAVR is involving the open chest surgery to replace the aortic valve.\n\nThe devices and international procedures in this Trial (TAVR or SAVR) are commercially approved by the FDA.\n\nConsented patients who are qualifying for the Trial will be randomized 1:1, meaning they will have an equal chance to be treated with either TAVR or SAVR procedure.\n\nConsented patients who will not qualify for the randomized part of the study will be followed up clinically in either TAVR or SAVR Registry arms.\n\nThe study objective is to provide evidence to guide patients and their providers on the most appropriate therapy for valve replacement on this particular BAV anatomy.",[246],"Bicuspid Aortic Valve Disease",[248],"Severe Bicuspid Aortic Valve intervention: TAVR vs SAVR","2026-05-07",{"date":251,"type":41},"2026-05-12",{"date":71,"type":23},{"date":254,"type":23},"2040-05-10",{"name":47,"class":48},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":24,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":278,"leadSponsor":279,"locationsCount":4},"100636478","phase-2-using-mirabegron-to-control-arrhythmia-1-100636478","NCT07566208","Using Mirabegron to Control Arrhythmia-1","MACH-1","Inclusion Criteria:\n\n* In order to be eligible to participate in this study, an individual must meet all the following criteria:\n\n  1. Provision of signed and dated informed consent form.\n  2. Age \\> 18 years old.\n  3. Documented VT on ICD.\n\n     1. with \\> 2 episodes of VT per month (on average) over the past 2 months.\n     2. despite guideline-recommended medical therapy (GRMT).\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  1. Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.\n  2. Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illness requiring hospitalization)\n  3. Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)25\n  4. Active thyrotoxicosis\n  5. Any experimental medication concomitantly or within 4 weeks of participation in the study\n  6. Currently participating in a different clinical trial\n  7. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  8. Hepatic disease (Child-Pugh Class C)\n  9. Pregnant\n  10. Breastfeeding\n  11. Cannot speak, write, and answer questions in English\n  12. Does not have the capacity to consent\n  13. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n  14. Hepatic disease (Child-Pugh Class C)\n  15. Pregnant\n  16. Breastfeeding\n  17. Cannot speak, write, and answer questions in English\n  18. Does not have the capacity to consent\n  19. Patients who are known to be allergic to mirabegron or skin patch electrodes\n  20. Patients taking codeine, oxycodone, thioridazine, flecainide, propafenone, and digoxin. (see explanation below)",{"count":264,"type":23},20,[26],"To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.",[268],"Ventricular Arrhythmias and Cardiac Arrest",[270,271,272,273],"mirabegron","Ventricular tachycardia","Ventricular fibrillation","ICD","2026-05-04",{"date":276,"type":41},"2026-05-06",{"date":228,"type":23},{"date":230,"type":23},{"name":47,"class":48},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":24,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":301},"100493684","phase-2-a-phase-2-study-of-the-ketogenic-diet-vs-standard-anti-cancer-diet-guidance-for-patients-with-glioblastoma-in-combination-with-standard-of-care-treatment-100493684","NCT05708352","A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment","A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment","Inclusion Criteria:\n\n* Adults 18 years or older\n* Newly diagnosed glioblastoma (Within 2 months of initial diagnosis by histopathology)\n* Not started standard of care chemotherapy and\u002For radiation therapy for glioblastoma\n* Karnofsky Performance Status (KPS) ≥ 70\n* Ability to read, write and understand either English OR Spanish\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Patients with recurrent glioblastoma\n* Genetic disorders that affect lipid metabolism. Including but not limited to pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase I or II deficiency, carnitine translocase deficiency, beta-oxidation defects\n* Inability to wean steroids below 8mg dexamethasone \u002F day or equivalent\n* Body Mass Index (BMI) \\\u003C 21kg\u002Fm2, unless the site Principal Investigator deems safe\n* Currently pregnant or nursing\n* Patients receiving other experimental therapy Note: Off-label therapy use is permitted\n* Comorbidities that in the opinion of the investigator limit the patient's ability to complete the study\n* Food preferences incompatible with keto diet\n* Using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants (removable hearing aids permitted), or other electronic medical equipment, unless the site Principal Investigator deems safe\n* Inability to participant in standard of care MRIs",{"count":288,"type":23},170,[26],"This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence.\n\nThis two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.",[292],"Glioblastoma Multiforme",[294],"Keto Diet",{"date":276,"type":41},{"date":297,"type":41},"2023-06-27",{"date":299,"type":23},"2029-09-30",{"name":47,"class":48},5,{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":49},"100445885","early-phase-1-feasibility-study-of-oral-ketamine-versus-placebo-for-the-treatment-of-anxiety-in-patients-with-pancreatic-cancer-100445885","NCT05086250","Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n1. Ability to understand and the willingness to sign a written informed consent.\n2. Participant has been diagnosed with pancreatic cancer.\n3. Receiving or within twelve weeks of having received cancer targeted treatment, including surgery, radiation, chemotherapy, immunotherapy, or other cancer targeted therapy.\n4. Age ≥ 18 years.\n5. Has moderate to severe anxiety according to the PROMIS Anxiety Short Form 7a and\u002For PROMIS-29 anxiety module (T-score of \\> 60).\n6. Documented adequate liver function within the screening period.\n7. Use of concomitant standard antidepressants targeting anxiety (e.g. SSRIs) is permitted if dose has been the same for at least 12 weeks prior to study entry and patient still meets inclusion #5.\n8. Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and while receiving study drug. Women of child-bearing potential must have a negative urine or blood pregnancy test at screening. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician and study staff immediately.\n9. Must be able to read and understand English.\n10. Required not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, after receiving a medication dose until the next day after a restful sleep (as per recommendations with Spravato).\n11. Agrees to abstain from alcohol use while taking study medication.\n\nExclusion Criteria:\n\n1. Initial cancer diagnosis ≤6 weeks prior to Day 0.\n2. Meets MINI International Neuropsychiatric Interview (MINI Plus), criteria for diagnoses of schizophrenia, bipolar illness, delirium or psychosis.\n3. Scores ≥ 10 on the Suicidal Risk Assessment (SRA).\n4. History of allergic reactions or hypersensitivity to ketamine.\n5. Documented history of severe cardiac insufficiency (NYHA III or IV), with currently uncontrolled and\u002For unstable cardiac or coronary artery disease.\n6. Current or recent significant tachyarrhythmia, severe angina, or myocardial ischemia, as assessed by a study physician.\n7. Documented history of poorly controlled hypertension (Systolic Blood Pressure \\> 180 mmHG or Diastolic Blood Pressure \\> 100 mmHG twice within a one-month period in last two months), with or without antihypertensives.\n8. Women who are pregnant or nursing or expect to become pregnant or start nursing during the expected trial duration, and women of childbearing potential who refuse to use contraceptives to prevent childbearing.\n9. Uncontrolled hypo- or hyperthyroidism, as assessed by a study physician.\n10. Diagnosis of dementia.\n11. Treatment with monoamine oxidase inhibitor (MAOI) within 14 days of Day 0.\n12. Aneurysmal vascular disease (including thoracic and abdominal aorta, intracranial and peripheral arterial vessels) or arteriovenous malformation.\n13. History of intracerebral hemorrhage.\n14. Refusal\u002Finability to comply with inclusion criterion #10 (driving restrictions) and inclusion criterion #11 (alcohol abstinence) during study treatment period.",{"count":264,"type":23},[311],"EARLY_PHASE1","This is a prospective, single center, double blind, randomized, crossover feasibility study of oral ketamine versus placebo for the treatment of anxiety in patients with pancreatic cancer currently receiving or within 12 weeks of receiving cancer targeted therapy. The primary objective is to determine the feasibility of enrolling subjects and treatment adherence. The secondary objectives are to describe the safety and tolerability. Exploratory objectives are to assess the effect of ketamine\u002Fplacebo on Depression, Anxiety, Physical Function, Pain Interference, Pain Intensity, Fatigue, Sleep Disturbance, and Ability to Participate in Social Roles and Activities as measured by PROMIS Anxiety Short Form 7a and the PROMIS-29 Profile v2.1 of Patient Reported Outcomes, as well as changes in circulatory inflammatory cytokines, blood glutamine levels, and other biomarkers of anxiety and\u002For depression.",[195,314],"Pancreatic Cancer",[316,317],"ketamine","placebo",{"date":319,"type":41},"2026-05-08",{"date":321,"type":41},"2022-10-20",{"date":323,"type":23},"2026-12",{"name":47,"class":48},{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":344,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":355},"100535953","phase-2-same-in-prevention-of-oxaliplatin-associated-liver-injury-100535953","NCT06258525","SAMe in Prevention of Oxaliplatin-associated Liver Injury","A Phase II, Open-Label Trial of S-Adenosylmethionine (SAMe) in Prevention of Oxaliplatin Associated Liver Injury","Inclusion Criteria:\n\n* Stage IV patients with resectable liver predominant metastatic colorectal cancer (new diagnosis or recurrent) referred to Cedars Sinai Medical Center for oxaliplatin based systemic therapy.\n* Age ≥ 18 years.\n* Patients who are planning to undergo liver resection following oxaliplatin based chemotherapy treatment.\n* ECOG Performance Status 0-2 or Karnofsky Performance Status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function (within 28 days of study treatment initiation)\n* Female subjects of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication for eligibility verification purposes. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Female subjects of childbearing potential should be willing to use adequate methods of birth control (hormonal or barrier method of birth control) or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year.\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of therapy through 120 days after the last dose of therapy.\n* Subjects taking vitamin E ≥800 IU\u002Fday must be on a stable dose defined as:\n\n  1. No changes in prescribed dose within 180 days of the screening visit and\n  2. No new vitamin E-containing medications within 180 days of the screening visit or\n  3. Discontinuation of vitamin E ≥800 IU\u002Fday for at least 180 days prior to the screening visit.\n* Subjects taking anti-diabetic medications must be on a stable dose for at least 90 days prior to the date of the screening visit.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.\n* No other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) or investigational agent may be used from 28 days prior to registration and until the end-of-study visit.\n* Has previously received chemotherapy for metastatic disease (neoadjuvant or adjuvant therapy is allowed as long as treatment was completed ≥6 months prior to recurrence).\n* Has pre-existing grade ≥ 3 neuropathy precluding use of oxaliplatin.\n* Has known additional malignancy that is progressing or requires active treatment.\n* Has a known hypersensitivity to any of the study supplement\u002Fdrugs (SAMe, oxaliplatin, flourouacil, folinic acid and capecitabine).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has any gastrointestinal disorder (e.g., bowel obstruction) or neurologic condition (e.g., oropharyngeal dysphagia) that may result in impairment of oral intake, inability to swallow the oral supplement, and\u002For impairment of absorption of study drug in the opinion of the treating investigator.\n* Has previous clinical diagnosis of cirrhosis, has had known history of Hep A\u002FB\u002FC or nonalcoholic fatty liver disease (NAFLD), liver transplantation, or any other cause for decompensated liver disease.\n* Known human immunodeficiency virus (HIV) infection.\n* Any of the following within 6 months prior to the screening visit: unstable cardiovascular disease, myocardial infarction, coronary artery bypass surgery, coronary angioplasty, transient ischemic attack, or cerebrovascular accident.\n* Any other condition that, in the investigator's opinion, would impede competence or compliance or delay completion of the study.\n* History of Parkinson's disease or bipolar disorder.\n\nPatients taking the following prohibited medications:\n\n* Olanzapine\n* MAO inhibiters, including:\n\n  * Isocarboxazid\n  * Linezolid\n  * Methylene blue injection\n  * Phenelzine\n  * Rasagiline\n  * Selegiline\n  * Tranylcypromine\n  * Any other MAO inhibitors The above prohibited medications cannot be taken -14 days prior to Day 0 and during study treatment.. Patients currently on or plan to be prescribed anti-psychotic medications not listed above may be excluded at the discretion of the Investigator. - Active infection as evidenced by positive urine culture, blood culture, or pneumonia.",{"count":333,"type":23},30,[26],"This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.",[337,338,339,340,341,342,343],"Colorectal Cancer","Liver Metastases","Liver Metastasis Colon Cancer","Liver Injury","Sinusoidal Obstruction Syndrome","5-Fluorouracil Toxicity","Liver Toxicity, Chemically-Induced",[345,346,347],"S-adenosylmethionine","Oxaliplatin","Stage IV colorectal cancer","2026-05-01",{"date":276,"type":41},{"date":351,"type":23},"2026-07",{"date":353,"type":23},"2028-08",{"name":47,"class":48},2,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":24,"phases":365,"briefSummary":366,"conditions":367,"keywords":369,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":49},"100255866","active-surveillance-of-papillary-thyroid-microcarcinoma-100255866","NCT02609685","Active Surveillance of Papillary Thyroid Microcarcinoma","PMCAS","Inclusion Criteria:\n\n* Pathologically confirmed Bethesda V or VI thyroid nodules with papillary thyroid carcinoma or high clinical suspicion, or pathologically confirmed Bethesda III or IV nodules with BRAF mutation.\n* 2.0 cm or smaller nodules by ultrasonographic criteria\n* Ability to understand and the willingness to sign a written informed consent and HIPAA Authorization form\n* Must be able to read and write English fluently to participate in the questionnaire portion of the study\n\nExclusion Criteria:\n\n* High-grade or poorly differentiated PTC variants\n* Central or lateral neck lymphadenopathy suspicious for PTC\n* Unfavorable nodule location (e.g. Near dorsal surface (by recurrent laryngeal nerve); Adjacent to trachea (risk of cartilage invasion)\n* History of radiation to neck",{"count":364,"type":23},216,[90],"The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.",[368],"Papillary Thyroid Microcarcinoma",[370,371,372],"Thyroid cancer","Active surveillance","PTMC",{"date":249,"type":41},{"date":375,"type":41},"2016-05-13",{"date":377,"type":23},"2030-12",{"name":47,"class":48},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":18,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":49},"100636212","empowered-relief-study-100636212","NCT07562750","Empowered Relief Study","Empowered Relief for Osteoarthritis (OA)","Inclusion Criteria:\n\n* Adults age 18 or older who are eligible and interested in enrolling\n\nExclusion Criteria:\n\n* Any records flagged \"break the glass\" or \"research opt out\"",{"count":387,"type":23},100,[90],"\"Empowered Relief\" (ER) Intervention was developed by Beth Darnall, PhD at what is now the Stanford Pain Relief Innovations Lab. Our design is a randomized 3-arm study with test treatment, active control, and placebo arms. Our goals are to provide scientific evidence to demonstrate the efficacy of ER, and also provide a comparison of said efficacy against the standard of care - group pain-CBT. Treatment allocation is randomized to minimize confounder effects. Statisticians performing analyses will be blinded.\n\nThe primary objective of this study is to evaluate the efficacy of Empowered Relief (a novel, single-session (2-hour), evidence-based online pain management class) on reducing pain burden and improving quality of life in patients with advanced osteoarthritis. Empowered Relief is designed to compress key cognitive behavioral therapy (CBT) skills, mindfulness principles, and pain neuroscience education into a brief, scalable format.\n\nSpecifically, the study aims to: Evaluate Clinical Outcomes: Determine whether the intervention reduces pain burden and enhances mobility.\n\nAssess Psychological \\& Behavioral Impact: Examine whether the intervention improves patient-reported understanding of pain, fosters self-efficacy, and increases perceived control, thereby promoting active engagement in their own pain management.\n\nSubject Population: The subject population consists of adult patients diagnosed with advanced osteoarthritis (KL Grade 3-4) who have been deferred from total hip or total knee arthroplasty (THA\u002FTKA). Deferment criteria for this population include existing medical, surgical, behavioral, or personal barriers that currently preclude them from undergoing joint replacement surgery. This population is particularly vulnerable to prolonged suffering, decreased mobility, and compounding psychosocial distress while managing severe somatic pain without immediate surgical options.\n\nMain Research Procedures: The study will utilize a prospective, longitudinal design to measure the impact of the Empowered Relief intervention on the target population.\n\nThe main procedures include: Intervention Delivery: Eligible participants will complete the live Empowered Relief online class (via Zoom) with a certified instructor (Dr. Caryn Lindsey), a 2-hour intervention equipping them with accessible, evidence-based behavioral pain management skills.\n\nData Collection Schedule: Participants will be assessed at three distinct time points: Baseline (pre-intervention), 4-weeks post-treatment, and 8-weeks post-treatment.",[391],"Osteoarthritis (OA)","2026-04-28",{"date":348,"type":41},{"date":395,"type":23},"2026-04-14",{"date":397,"type":23},"2028-04-16",{"name":47,"class":48},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":408,"briefSummary":409,"conditions":410,"keywords":414,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":423,"completionDateStruct":425,"leadSponsor":427,"locationsCount":428},"100594302","phase-2-phase-ii-trial-of-ivonescimab-in-combination-with-carboplatin--docetaxel-in-patients-with-early-stage-triple-negative-breast-cancer-100594302","NCT07017673","Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer","Inclusion Criteria\n\n* Age ≥ 18 years of age\n* ECOG ≤ 1\n* High-risk early stage triple negative breast cancer (TNBC), defined by ER≤10%, PR≤10% and HER2 negative (by IHC or FISH), per ASCO\u002FCAP guidelines\n* Clinically ≥T1cN0, or any T, N1-2\n* Plan to receive neoadjuvant chemotherapy and immune checkpoint inhibitor before surgery as standard-of-care treatment\n* Adequate organ function as defined in the following. Specimens must be collected within 14 days prior to the start of study treatment.\n\n  * ANC ≥ 1,500\u002Fmm3\n  * Platelets ≥ 100,000\u002Fmm3\n  * Hemoglobin ≥ 9.0 g\u002FdL.\n  * Total serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 x ULN\n  * AST \\\u003C 3 x ULN\n  * ALT \\\u003C 3 x ULN\n  * Creatinine clearance ≥ 30 mL\u002Fmin\n  * INR or PT, aPTT \\\u003C 1.5 x ULN\n* Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 14 days of start of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: If egg harvesting was completed prior to enrollment, the pregnancy test may be falsely positive and the PI will assess and determine eligibility for these cases.\n* Female participants: A female participant is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding, and at least one of the following conditions applies:\n\n  \\-- Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR Females of child-bearing potential must be willing to use effective contraception during study and for 120 days after the last dose.\n* Male participants: A male participant must agree to use a contraception as detailed in Appendix B of this protocol during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria\n\n* Evidence of metastatic disease.\n* Is currently participating in or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n* History of bleeding tendencies or coagulopathy and\u002For clinically significant bleeding symptoms or risk within 4 weeks prior to start of study treatment, including but not limited to:\n\n  * Hemoptysis (defined as coughing up ≥ 0.5 teaspoon of fresh blood or small blood clots) Note: transient hemoptysis associated with diagnostic bronchoscopy is allowed.\n  * Nasal bleeding\u002Fepistaxis (bloody nasal discharge is allowed)\n  * Current use of prophylactic or full-dose anticoagulants or anti-platelet agents for therapeutic purposes that is not stable, in the opinion of the treating investigator, prior to start of study treatment is not allowed. The use of full-dose anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits according to the medical standard of the enrolling institution.\n* Poorly controlled hypertension with repeated systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg after oral antihypertensive therapy\n* Women who are or are planning to become pregnant or breastfeed\n* Known allergy to any of the components within the study agents and\u002For their excipients\n* Medical history and concurrent diseases\n\n  * Autoimmune diseases\n  * Any prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years\n  * History of (non-infectious) pneumonitis that required steroids or has current pneumonitis\n  * Active infection requiring systemic therapy\n  * Known history of Human Immunodeficiency Virus (HIV) infection\n  * Known history of active Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive) or known active Hepatitis C virus (defined as HCV RNA \\[qualitative\\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority\n  * Known history of active TB (Mycobacterium tuberculosis)\n  * History of unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \\[NYHA\\] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 12 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia)\n  * Prolongation of QTc interval \\>480 msec\n  * Prior allogeneic bone marrow transplantation or prior solid organ transplantation\n  * History of esophageal gastric varices, severe ulcers, wounds that do not heal, abdominal fistula, intra-abdominal abscesses, or acute gastrointestinal bleeding within 6 months prior to start of study treatment\n  * History of any grade arterial thromboembolic event, Grade 3 and above venous thromboembolic event, as specified in National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy within 12 months prior to start of study treatment\n  * Acute exacerbation of chronic obstructive pulmonary disease within 4 weeks before start of study treatment\n  * History of perforation of the gastrointestinal tract and\u002For fistula, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection) within 6 months prior to start of study treatment\n* Prohibited Treatments and\u002For Therapies\n\n  * Other non-protocol specified anti-cancer therapy: systemic radiotherapy, immunotherapy, biologic, or hormonal therapy. tretinoin therapy, nitrosourea, mitomycin C, small molecule tyrosine kinase inhibitor therapy\n\n    \\--- Concomitant use of hormones for non-tumor-related conditions (e.g., insulin and hormone replacement therapy for diabetes mellitus) is acceptable\n  * Any live vaccine within 30 days prior to the first dose of study drug and up to 120 days after the last dose. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella\u002Fzoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed\n  * Prior systemic therapy or radiation therapy with curative intent for the current breast cancer\n  * A previous definitive ipsilateral breast surgery for the current breast cancer\n  * Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137).\n  * Immunosuppressive drugs, including, but not limited to, prednisone or equivalent, methotrexate, azathioprine, and TNF-α antagonists at doses exceeding 10 mg per day. The following exceptions are allowed:\n\n    * The use of immunosuppressive drugs for the treatment of study drug-associated AEs or the use of immunosuppressive drugs in subjects with contrast allergy is acceptable.\n    * The use of inhaled, topical, and intranasal glucocorticoids is permitted.\n    * Corticosteroids are allowed as a prophylactic drug for hypersensitivity reactions (eg, before CT or MRI).\n    * Corticosteroids are allowed as antiphylactic and therapeutic agents for chemotherapy-induced vomiting.\n    * Short-term use of glucocorticoids for underlying or intercurrent conditions may be permitted after discussion with the PI.\n* Major surgery within 28 days prior to start of study treatment and within 4 weeks after first dose. Participants must have fully recovered from the effects of prior major surgery in the opinion of the treating investigator.\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.",{"count":407,"type":23},34,[26],"This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer. The trial is designed to test the safety and efficacy of adding ivonescimab in patients with early TNBC undergoing neoadjuvant chemotherapy with carboplatin and docetaxel. Patients will receive ivonescimab 20 mg\u002Fkg IV on Day 1 of each cycle, and carboplatin AUC6 and docetaxel 75 mg\u002Fm2 on Day 1 of each cycle for 6 cycles. Cycles will be 21 days for a total of 6 cycles. Curative intent surgery will be performed within 6 weeks (maximum 12 weeks) time frame upon completion of last dose of chemoimmunotherapy. The surgical pathology information will be used for assessment of pathological response, which serve as the primary endpoint of this study. Patients will undergo assessment at baseline, C1D1 of each cycle and end of treatment visit for collection of treatment-emergent adverse events, evaluated by CTCAE v5.0. Patient reported outcomes will be collected at cycles 1, 4, and 6, and at EOT. All study patients will be followed for at least 5 years for EFS and OS follow up. Research biopsies, peripheral blood and stool samples will be collected at the following time points: baseline, C4D1 (+\u002F-14 days), and surgery (+\u002F-14 days). Baseline and EOT breast MRI will be performed as standard of care for assessment of clinical response. Mid treatment breast ultrasound (C4D1 +\u002F-14 days) will be repeated as standard of care to assess clinical response to treatment. Mid-treatment C4D1 tumor biopsy may be omitted if the primary tumor is no longer visible or the tumor deemed too small for biopsy by radiologist.",[411,412,413],"TNBC","TNBC - Triple-Negative Breast Cancer","Early Stage Triple-Negative Breast Carcinoma",[415,416,417,418,411,419],"Ivonescimab","Carboplatin","Docetaxel","Neoadjuvant chemotherapy","High-risk early stage TNBC","2026-04-01",{"date":422,"type":41},"2026-04-02",{"date":424,"type":41},"2025-07-25",{"date":426,"type":23},"2032-11",{"name":47,"class":48},4,{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":24,"phases":439,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":4},"100631078","phase-2-same-for-prevention-of-liver-cancer-in-masld-related-cirrhosis-100631078","NCT07495995","SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis","A Single-center, Phase II Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Effect of S-adenosyl-L-methionine (SAMe) in Prevention of Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD)-Related Cirrhosis","SAMeMASLDc-02","Inclusion Criteria:\n\n1. individuals 18 years old or above.\n2. Understand the study procedures and able to provide informed consent.\n3. Clinical diagnosis of MASLD per American Association for the Study of Liver Diseases (AASLD) guideline: Patients with hepatic steatosis identified by imaging or biopsy, AND have at least one of five cardiometabolic risk factors:\n\n   (i) BMI ≥25 kg\u002Fm2 (23 kg\u002Fm2 for Asian) OR waist circumference \\>94 cm for male or \\>80 cm for female.\n\n   (ii) Fasting serum glucose ≥5.6 mmol\u002FL (100 mg\u002FdL) OR 2-hour post-load glucose levels ≥7.8 mmol\u002FL (140 mg\u002FdL) OR HbA1c ≥5.7% (39 mg\u002FdL) OR type 2 diabetes OR treatment for type 2 diabetes (iii) Blood pressure ≥130\u002F85 mmHg OR specific antihypertensive drug treatment. (iv) Plasma triglycerides ≥1.7 mmol\u002FL (150 mg\u002FdL) OR lipid lowering treatment (v) Plasma HDL-cholesterol ≤1.0 mmol\u002FL (40 mg\u002FdL) for male or ≤1.3 mmol\u002FL (50 mg\u002FdL) for female OR lipid lowering treatment.\n4. Current weekly intake of alcohol \\\u003C210 g (7.41 oz) for male or weekly intake of alcohol \\\u003C140 g (4.76 oz) for female, \\[1 oz\u002F30 mL of alcohol is present in one 12 oz\u002F360 mL beer, 4 oz\u002F120 mL glass of wine, and a 1oz\u002F30 mL measure of 40 proof (20%) alcohol\\]\n5. Diagnosis of cirrhosis confirmed via histopathology OR at least two of the following measures:\n\n   (i) Transient elastography (FibroScan® ≥ 12 kPa) (ii) Computed tomography (iii) MRI including MR elastography (stiffness ≥ 4.71 kPa) (iv) Abdominal Ultrasound\n6. Patient had imaging for HCC screening (Ultrasound or MRI or CT) within 3 months prior to screening.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of HCC prior to screening, any suspicious nodules identified prior or during screening must be followed with documentation of HCC negative confirmed prior to randomization.\n2. History of other causes of liver disease, including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders (primary biliary cholangitis, primary sclerosing cholangitis, or autoimmune hepatitis), drug-induced hepatotoxicity, Wilson's disease, iron overload, or alpha-1-antitrypsin deficiency.\n3. Most recent serum creatinine \\>1.5 mg\u002Fdl within 3 months prior to screening.\n4. Active infection with positive urine culture, blood culture, or pneumonia at screening.\n5. History of gastrointestinal bleeding within the prior 28 days\n6. History of liver transplantation.\n7. Women who are pregnant or nursing at screening.\n8. Significant systemic illness including chronic obstructive pulmonary disease, congestive heart failure, and renal failure that in the opinion of the investigator would preclude the patient from participating in the study or poses a significant risk of mortality during the study period, such as conditions that are interfering with the absorption, distribution, metabolism, or excretion of S-adenosyl-L-methionine (SAMe) such as those with gastric bypass surgery.\n9. HIV infection or patients who are immunocompromised.\n10. Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening.\n11. Systemic antibiotic use or use of rifaximin for 10 days or more within the last 2 months prior to screening.\n12. Actively taking investigational or over-the-counter SAMe within 28 days prior to screening.\n13. Subjects with psychiatric illnesses such as bipolar disorders and Parkinson's disease as SAMe may interfere with the levels of anti-psychotic drugs and might interact with drugs and dietary supplements that increase levels of serotonin (a chemical produced by nerve cells), such as antidepressants, L-tryptophan, and St. John's wort.\n14. Members from the same family of study participant.",{"count":438,"type":23},94,[26],"This study will evaluate the safety, feasibility, and preliminary effects of S-adenosyl-L-methionine (SAMe) compared with placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis. Investigators will assess whether treatment is associated with changes in liver-related clinical measures, biologic markers, and other study outcomes relevant to disease progression. The goal of this study is to generate early data to determine whether SAMe should be studied further as a potential therapeutic strategy in patients with MASLD cirrhosis.",[442],"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","2026-03-26",{"date":445,"type":41},"2026-03-31",{"date":447,"type":23},"2026-04-15",{"date":449,"type":23},"2031-12-31",{"name":47,"class":48},{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":459,"minAge":86,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":462,"conditions":463,"keywords":466,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":472,"leadSponsor":474,"locationsCount":49},"100631316","together-breast-cancer-support-platform-100631316","NCT07499089","Together-Breast Cancer Support Platform","\"Together\": A Bilingual Online Platform Support Intervention Project for Korean Breast Cancer Survivors","Together","Inclusion Criteria:\n\nMentors:\n\n* Age ≥ 18 years\n* Self-identify as Korean\n* Able to read, write, and speak both Korean and English\n* Diagnosed with breast cancer ≥ 2 years prior to enrollment\n* Completed active treatment or currently on long-term maintenance therapy\n* Access to a smartphone, computer, or similar device compatible with the study platform\n* Willing to participate for at least 3 months\n* Willing to complete required training and surveys\n\nMentees:\n\n* Age ≥ 18 years\n* Self-identify as Korean\n* Able to read, write, and speak Korean\n* Diagnosed with breast cancer\n* Currently receiving treatment (e.g., chemotherapy, radiation therapy, recent surgery, or endocrine therapy)\n* Access to a smartphone, computer, or similar device compatible with the study platform\n* Willing to participate for at least 3 months\n* Willing to complete required surveys\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria\n* Individuals unable to use the online platform or required technology\n* Individuals deemed non-compliant or inappropriate for participation based on investigator judgment (e.g., inability to complete study procedures)\n* Mentees diagnosed with ductal carcinoma in situ (DCIS)","FEMALE",{"count":461,"type":23},24,"The goal of this study is to evaluate the acceptability and engagement of a culturally tailored online peer-support program for Korean speaking breast cancer patients and survivors. The main questions it aims to answer are: 1) Is the peer-support program acceptable and sustainable in terms of engagement between mentors and mentees over a 12-week period? 2) Does participation in the program improve quality of life, psychological well-being (including anxiety and depression), and perceived social support?\n\nParticipants will include Korean speaking breast cancer survivors (mentors) and patients currently undergoing treatment (mentees). After enrollment and matching based on screening information, participants will engage in peer-support interactions through an online platform for 12 weeks. Surveys will be administered at baseline, mid-point, post-intervention, and optional 6-month follow-up to assess outcomes.",[464,465],"Breast Cancer","Breast Cancer Survivors",[467],"Breast Cancer Survivorship, Korean American, Online peer support,","2026-03-24",{"date":470,"type":41},"2026-03-30",{"date":420,"type":23},{"date":473,"type":23},"2027-12-31",{"name":47,"class":48},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":4,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":482,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":355},"100503594","conservative-treatment-of-trigger-finger-100503594","NCT05837286","Conservative Treatment of Trigger Finger","Conservative Treatment of Trigger Finger: Outcomes of a Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals 18 years old or older are included\n* Patients with trigger finger, aka stenosing flexor tenosynovitis\n* Status post receiving cortisone injection of the affected digit(s)\n\nExclusion Criteria:\n\n* Any records flagged with break the glass or research opt out\n* Patients with rheumatoid arthritis\n* Patients with a history of traumatic injury to the hand\n* Cognitive or behavioral problems which would preclude informed consent\n* Unable to speak and understand English","100 Years",{"count":484,"type":23},146,[90],"This study is to analyze the effectiveness of a nighttime extension orthosis after receiving a cortisone injection for the treatment of trigger finger to improve pain and restore functional outcomes. The investigators hypothesize that the extension orthosis will improve pain and functional outcomes compared to those without a digital night extension orthosis in those with trigger finger at 12 weeks from the injection.",[488,489],"Hand Injuries","Trigger Finger",{"date":491,"type":41},"2026-03-27",{"date":493,"type":41},"2023-08-01",{"date":495,"type":23},"2026-05-31",{"name":47,"class":48},{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":504,"targetDuration":4,"studyType":24,"phases":505,"briefSummary":506,"conditions":507,"keywords":510,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":355},"100517339","using-virtuacaretm-platform-for-home-programs-in-acute-and-chronic-shoulder-conditions-a-pilot-study-100517339","NCT06016257","Using VirtuaCareTM Platform for Home Programs in Acute and Chronic Shoulder Conditions: A Pilot Study","VirtuaCare","Inclusion Criteria:\n\nPhysical therapy home program subjects\n\n* Subject 18 years or older\n* Outpatient physical therapy prescribed by doctor for shoulder rehabilitation.\n* No previous neurological condition\n* Understand English (exercises are only in English) Physical therapists\n* The therapists will be the ones who provide physical therapy treatment to the acute and chronic shoulder population.\n\nPatients who had usual and customary treatment for acute and chronic shoulder conditions\n\n• Any patient referred based on inclusion criteria noted above that are referred for outpatient physical therapy and had a previous acute or chronic shoulder condition, were 18 years and older and had no previously documented neurological condition.\n\nExclusion Criteria:\n\nPhysical therapy home program subjects\n\n* Prior surgery within the last 5 years or less than 6 months between surgery\n* Neurologic comorbidities that have functional deficits\n* Uncontrolled diabetes\n* Diagnosis with active cancer in the last two years\n* Unable to understand English\n\nPhysical therapists • Any therapist who does not provide physical therapy treatment for acute and chronic shoulder conditions.\n\nPatients who had usual and customary treatment for acute and chronic shoulder conditions\n\n• Any patient who had prior surgery within the last 5 years or less than 6 months between surgery, had neurological comorbidities that had documented functional deficits, documented uncontrollable diabetes, documented diagnosis of active cancer within the last two years.",{"count":264,"type":23},[90],"This study will be performed to determine if Band Connect's VirtuaCare™ platform increases patient compliance and provides an effective alternative to current physical therapy treatment while reducing the frequency of visits compared with standard orthopedic physical therapy treatment performed in the outpatient clinic.\n\nParticipants are being asked to take part in this research study if 18 years and older and have been prescribed physical therapy rehabilitation for an acute or chronic shoulder condition and as part of the participant's physical therapy will receive a shoulder exercise home program.",[508,509],"Shoulder Disease","Shoulder Injuries",[511,512,513],"Home program","Shoulder conditions","Adherence","2026-03-23",{"date":491,"type":41},{"date":517,"type":41},"2024-02-01",{"date":519,"type":23},"2026-12-31",{"name":47,"class":48},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":18,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":49},"100102642","pituitary-tumor-surveillance-pathogenic-correlation-100102642","NCT00599092","Pituitary Tumor Surveillance: Pathogenic Correlation","Pituitary Tumor Surveillance: Pathogenetic Correlation","Inclusion Criteria:\n\n* patients with confirmed pituitary disease\n\nExclusion Criteria:\n\n* patients who do not have confirmed pituitary disease",{"count":529,"type":23},1250,"The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.",[532],"Pituitary Tumor",[534,535],"pituitary tumor","recurrence","2026-03-19",{"date":514,"type":41},{"date":539,"type":4},"1997-01",{"date":541,"type":23},"2050-12",{"name":47,"class":48},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":558,"lastUpdatePostDateStruct":559,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":564,"locationsCount":49},"100605969","food-is-medicine-prospective-study-100605969","NCT07169448","Food is Medicine Prospective Study","Impact of A Postoperative Meal Delivery Program on Malnutrition in Orthopaedic Trauma Patients","FIM","Inclusion Criteria:\n\n* Individuals 18 years old or older are included.\n* English or Spanish speaking\n* Reside in the following zip codes: 90001, 90002, 90003, 90004, 90005, 90006, 90007, 90008, 90009, 90010, 90011, 90012, 90013, 90014, 90015, 90016, 90017, 90018, 90019, 90020, 90021, 90023, 90026, 90027, 90028, 90029, 90031, 90035, 90036, 90037, 90038, 90039, 90043, 90044, 90046, 90047, 90048, 90052, 90057, 90059, 90061, 90062, 90065, 90068, 90069\n* Discharged home, either directly from Cedars-Sinai Medical Center or after time in a skilled nursing facility or acute rehab\n* Orthopaedic trauma surgical patients that have had an operation and inpatient stay at Cedars-Sinai Medical Center\n\nExclusion Criteria:\n\n* Any records flagged \"break the glass\" or \"research opt out.\"\n* Any pregnant patients.\n* Patients with any congenital metabolic conditions\n* Patients with dietary restrictions (ex. Kosher, Halal, vegan, gluten free, etc.) that are unable to be reasonably accommodated by St. Vincent Meals on Wheels\n* Any patients with mental illness the prevents them from giving consent.\n* Patients with dementia or cognitive impairment.\n* Patients who are homeless and\u002For unreliable to follow up",{"count":552,"type":23},75,"The purpose of this study is to examine the impact of a medically tailored post-operative meal delivery program on surgical outcomes and metabolic lab markers in orthopaedic trauma patients. Patients will have 12 days of meals and shakes delivered to their house through our partnership with Meals on Wheels. Metabolic lab values will be drawn at the 2 week and 6 week post-op visits. All patients will be followed for up to 1 year postoperatively.",[555],"Wounds and Injuries",[557],"Food is medicine","2026-03-18",{"date":560,"type":41},"2026-03-20",{"date":562,"type":41},"2025-09-01",{"date":107,"type":23},{"name":47,"class":48},{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":570,"acronym":4,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":585,"leadSponsor":587,"locationsCount":49},"100620218","precise-cooler-for-donor-heart-transport-100620218","NCT07354763","Precise Cooler for Donor Heart Transport","Adjustable Temperature Cooler for Cold Static Storage of Donor Hearts for Transplantation","Inclusion Criteria:\n\n* Individuals 18 years old or older are included.\n* Individuals undergoing isolated heart transplantation are included.\n\nExclusion Criteria:\n\n* Any records flagged \"break the glass\" or \"research opt out.\"\n* Any patients undergoing multi-organ transplantation.",{"count":59,"type":23},[90],"The investigators are doing this study to compare approaches to cold storage of donor hearts during transportation. The adjustable temperature RYOBI cooler should allow precise temperature control while reducing environmental waste and providing a cost savings benefit when compared to the commercially available, FDA-approved Paragonix SherpaPak device.",[576],"Heart Transplantation",[578,579,580,581],"Donor heart","Heart transplantation","organ procurement","heart failure","2026-03-17",{"date":558,"type":41},{"date":420,"type":23},{"date":586,"type":23},"2027-12-01",{"name":47,"class":48},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":4,"eligibilityCriteria":594,"healthyVolunteers":18,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":49},"100620420","virtual-reality-for-icu-delirium-prevention-100620420","NCT07357389","Virtual Reality for ICU Delirium Prevention","VR for ICU Delirium Prevention","Inclusion Criteria:\n\n* Individuals who are currently admitted to the SICU at Cedars-Sinai Medical Center\n* Expected ICU stay \\>48 hours\n* Richmond Agitation Sedation Scale (RASS) score between -1 to +2.\n* CAM-ICU negative\n* 1≤ risk factor for delirium (Age ≥ 65 years old, history of cognitive impairment, sepsis, Sequential Organ Failure Assessment (SOFA) score \\>5, history of alcohol or benzodiazepine abuse, recent major surgery)\n\nExclusion Criteria:\n\n* Unwilling and\u002For unable to participate\n* Intubation of tracheostomy\n* Self-reported history of severe motion sickness\n* Inability to follow commands (e.g. severe aphasia, deafness, GCS\\\u003C13)\n* The presence of a facial\u002Fhead deformity that will prohibit the wearing of a VR head mounted device (HMD\n* Those that require corrective lenses -2.5 or stronger that cannot be corrected with contact lenses\n* Having had a seizure in the past year\n* Unable to understand the instructions or to consent to participation in the study.\n* Those who are pregnant\n* Hemodynamic instability (MAP\\\u003C65 despite support)\n* End-of-life care\n* Severe agitation or delirium (i.e. CAM-ICU + screen)",{"count":596,"type":23},822,[90],"The purpose of this study is to evaluate whether daily exposure to immersive virtual reality (VR) can reduce the incidence of delirium in high-risk, non-intubated ICU patients. Participants will be randomized to either standard ICU care or standard care plus once-daily 15-minute VR sessions consisting of calming natural scenes, guided meditation, and music. The study population includes adult surgical ICU patients at Cedars-Sinai who are CAM-ICU negative at enrollment and possess at least one established risk factor for delirium. Outcomes will include the incidence and duration of delirium, ICU and hospital length of stay, feasibility of the VR intervention, and the frequency of adverse events. By targeting a high-risk population with an innovative non-pharmacologic therapy, this trial aims to generate data to support integration of VR into ICU delirium prevention protocols.",[600],"ICU Delirium",[600,602],"Virtual Reality","2026-03-16",{"date":582,"type":41},{"date":606,"type":41},"2026-03-10",{"date":608,"type":23},"2028-04",{"name":47,"class":48},{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":19,"minAge":86,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":623,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":628,"locationsCount":49},"100590314","this-study-is-to-evaluate-whether-receiving-education-and-glucose-monitoring-with-the-cgm-device-will-improve-patient-reported-outcomes-by-improving-patients-satisfaction-and-quality-of-life-qol-with-glucose-monitoring-device-100590314","NCT06965803","This Study is to Evaluate Whether Receiving Education and Glucose Monitoring With the CGM Device Will Improve Patient-reported Outcomes by Improving Patient's Satisfaction and Quality of Life (QOL) With Glucose Monitoring Device","Continuous Glucose Monitor (CGM) Discharge Program","CGM QOL","Inclusion Criteria:\n\n* aged 18 or older\n* diagnosed with Type 1 or Type 2 Diabetes who are on insulin\n* able to speak and understand English language\n* scheduled to receive a standard inpatient diabetes education consultation\n* must not have used CGM in the six months prior to admission\n* owns a smartphone\n* demonstrates the ability to follow instructions and be capable of providing informed consent to participate in the program\n\nExclusion Criteria:\n\n* those who are known to be pregnant. This is due to complexity of pregnancy-related changes in glucose metabolism and increased skin sensitivity, or changes in skin condition to adhesives and materials used in CGM devices.\n* non-English speakers. As this is small study to evaluate which method is favorable using a survey only validated in English, enrolling non-English speakers would require additional resources\u002Ftranslations\u002Fpersonnel for evaluation and the education intervention that are not logistically possible right now.",{"count":619,"type":23},37,"The purpose of the study is to improve patient-reported outcomes by improving patient's satisfaction and quality of life (QOL) with glucose monitoring device through pre and post satisfaction survey of patient with diabetes.",[622],"Diabetes Mellitus",{"date":558,"type":41},{"date":625,"type":41},"2025-10-01",{"date":627,"type":23},"2026-12-30",{"name":47,"class":48},""]